New radioactive injection targets Hard-to-Treat breast cancer
NCT ID NCT07340424
First seen Jan 19, 2026 · Last updated May 18, 2026 · Updated 21 times
Summary
This early-phase trial tests the safety of a new radioactive drug, 225Ac-TR2205, in 15 women with advanced triple-negative breast cancer that has spread. The study aims to see if the treatment is tolerable and to measure how radiation moves through the body. It is not a cure, but a step toward better control of this aggressive cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, China
Conditions
Explore the condition pages connected to this study.